ERBB2 and breast carcinoma: The outcomes clearly demonstrated that the triple combination exerted significantly enhanced inhibitory effects on proliferation and colony formation in HR+/HER2-low breast cancer cells, surpassing the efficacy of CDK4/6 inhibitor combined with endocrine therapy alone (CI < 0.5, P < 0.01) (Fig. 4A,B).